Sodium-glucose Co-transporter-2 Inhibitors Causing Candida tropicalis Fungemia and Renal Abscess.

Autor:	Simhadri PK; Division of Nephrology, Advent Health/FSU School of Medicine, Daytona Beach, 32117 FL, USA., Vaitla P; Division of Nephrology, University of Mississippi Medical Center, Jackson, 39216 MS, USA., Sriperumbuduri S; Division of Nephrology, University of Mississippi Medical Center, Jackson, 39216 MS, USA., Chandramohan D; Division of Nephrology, University of Alabama School of Medicine, Birmingham, 35233 AL, USA., Singh P; Division of Nephrology, Christus Spohn Hospital, Corpus Christi, 78404 TX, USA., Murari U; Division of Nephrology, West Virginia University, Morgantown, 26506 WV, USA.
Jazyk:	angličtina
Zdroj:	JCEM case reports [JCEM Case Rep] 2024 Feb 01; Vol. 2 (2), pp. luae010. Date of Electronic Publication: 2024 Feb 01 (Print Publication: 2024).
DOI:	10.1210/jcemcr/luae010
Abstrakt:	Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are a relatively newer class of medications, approved by the U.S. Food and Drug Administration in 2013 to treat type 2 diabetes mellitus. Over the past few years, the indications for SGLT2i have been expanded to decrease the risk of kidney disease and cardiovascular disease. SGLT2i are associated with an increased risk of euglycemic diabetic ketoacidosis, urinary tract infections, and genital mycotic infections. There are a few case reports of severe invasive fungal infections due to Candida in patients using SGLT2i. We present the case of Candida tropicalis fungemia and renal abscess in a patient on an SGLT2i. (© The Author(s) 2024. Published by Oxford University Press on behalf of the Endocrine Society.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu